|
|
|
|
|
Vindesine
drug data and news
Vindesine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Vindesine | ||
| Brand Names/Synonyms | CHEMBANK3015; DAVA; Desacetylvinblastine Amide Sulfate; Desacetylvinblastine Amide Sulfate Compound with Mannitol; Eldesine; Eldisine; VINDESINE; Vindesine; Vindesine Sulfate | ||
| Indication | For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine. | ||
| Mechanism Of Action | Vindesine acts by causing the arrest of cells in metaphase mitosis through its interaction with tubulin. The drug is cell-cycle specific for the S phase. | ||
| Vindesine News (When available) |
Chemotherapy plus Immunotherapy May Not Improve Survival over ... Apr 21, 2006 | ||
| Dosage Forms | IV Solution; POWDER FOR SOLUTION | ||
| Drug_Category | Antineoplastic Agents; ATC:L01CA03 | ||
| Absorption | Not Available | ||
| Interactions | Drug Interactions: Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C43H55N5O7 | ||
| Molecular Weight | 753.926 g/mol | ||
| Smiles String | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O | ||
| Melting Point | 230-232 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.002 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 24 hours. | ||
| Protein Binding [%] | 65-75% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Vindesine.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00392 | ||
| CAS Registry Number | 59917-39-4 | ||
| KEGG Compound ID | D01769 | ||
| PubChem ID | SID:181645 | ||
| PharmGKB ID | PA10232 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 555665 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |